Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer
- Folprecht, G.
- Tabernero, J.
- Köhne, C.-H.
- Zacharchuk, C.
- Paz-Ares, L.
- Rojo, F.
- Quinn, S.
- Casado, E.
- Salazar, R.
- Abbas, R.
- Lejeune, C.
- Marimón, I.
- Andreu, J.
- Ubbelohde, U.
- Cortes-Funes, H.
- Baselga, J.
ISSN: 1078-0432
Argitalpen urtea: 2008
Alea: 14
Zenbakia: 1
Orrialdeak: 215-223
Mota: Artikulua